SCHEDULE: Farallon Capital Discloses 9.99% Stake in Beam Therapeutics

Farallon Capital Management, L.L.C. and associated entities have reported beneficial ownership of 9.99% of Beam Therapeutics Inc.'s common stock, as of June 30, 2026.

Summary

• Farallon Capital Management, L.L.C. and related entities (collectively, the 'Reporting Persons') have filed a Schedule 13G, indicating beneficial ownership of 10,282,210 shares of Beam Therapeutics Inc. common stock.
• This ownership stake represents 9.99% of the class of securities.
• The filing is an amendment (Amendment No. 6) and the event date requiring the filing is June 30, 2026.
• The Reporting Persons are investment managers and individuals associated with them.
• The shares are held through various investment partnerships managed by Farallon Capital Management, L.L.C.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a significant but not controlling stake in Beam Therapeutics Inc. without indicating immediate aggressive action.

Positives

• Farallon Capital, a significant investment firm, has taken a substantial stake in Beam Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The disclosure is transparent and follows regulatory requirements, providing clarity to the market regarding ownership.

Negatives

• The filing does not provide specific details on the investment strategy or the rationale behind acquiring this stake, leaving room for speculation.
• The aggregate beneficial ownership is at the 9.99% threshold, which is a common level for institutional investors but does not indicate control.

Risks

• The Beneficial Ownership Limitation of 9.99% on the exercise of Warrants means that the Reporting Persons cannot exercise all of their Warrants if it would exceed this threshold, limiting potential future share acquisition.
• Future actions by Farallon Capital, such as increasing or decreasing their stake, could impact Beam Therapeutics' stock price.

Future Outlook

The filing does not contain forward-looking statements or specific guidance from management regarding future performance. The primary forward-looking aspect relates to the potential exercise of warrants, which is capped by a beneficial ownership limitation.

Industry Context

StockSavvy.ai notes that significant stakes taken by established investment firms like Farallon Capital in biotechnology or life sciences companies are common, reflecting active portfolio management and strategic investment in the sector. Beam Therapeutics operates in the gene editing space, a highly dynamic and competitive field.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, but the 9.99% threshold suggests a significant investor rather than a controlling party. Future trading activity by Farallon could influence share price.
• Management: The filing provides transparency on a major shareholder's holdings, which is standard practice.

Next Steps

• The Reporting Persons will continue to monitor their beneficial ownership and may adjust their holdings in Beam Therapeutics.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership or other reportable events.

Key Dates

Keywords

Beam Therapeutics, Farallon Capital, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Warrants, Institutional Investor